Compass Therapeutics, Inc. (NASDAQ:CMPX) Position Increased by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,334,171 shares of the company’s stock after buying an additional 24,393 shares during the quarter. Geode Capital Management LLC owned 1.70% of Compass Therapeutics worth $3,386,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Independent Advisor Alliance purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $26,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $45,000. Bleakley Financial Group LLC lifted its position in shares of Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after purchasing an additional 28,589 shares in the last quarter. Catalina Capital Group LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $71,000. Finally, Intech Investment Management LLC lifted its position in shares of Compass Therapeutics by 218.7% in the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock worth $75,000 after purchasing an additional 35,632 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 8.5 %

Shares of Compass Therapeutics stock opened at $1.94 on Monday. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $4.08. The firm has a fifty day simple moving average of $2.23 and a 200-day simple moving average of $2.10. The stock has a market capitalization of $268.27 million, a price-to-earnings ratio of -5.24 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Insider Activity at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the business’s stock in a transaction dated Monday, April 7th. The stock was bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

CMPX has been the subject of a number of research analyst reports. D. Boral Capital reissued a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Guggenheim reaffirmed a “buy” rating on shares of Compass Therapeutics in a research report on Tuesday, April 22nd. Finally, Piper Sandler assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.